Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan

被引：0
|
作者：
Keiko Takata
Masami Nakazawa
Keiichi Honda
Sayo Hashimoto
机构：
[1] Shionogi Pharmacovigilance Center Co.,Postmarketing Surveillance & Pharmacoepidemiology Department
[2] Ltd,Pharmacovigilance Department
[3] Shionogi & Co.,undefined
[4] Ltd,undefined
来源：
Supportive Care in Cancer | 2022年 / 30卷
关键词：
Naldemedine; Cancer; Opioid-induced constipation (OIC); Post-marketing surveillance; Safety; Japan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3943 / 3954
页数：11
相关论文
共 50 条
  • [21] A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy
    Webster, Lynn R.
    Hale, Martin E.
    Yamada, Tadaaki
    Wild, James E.
    JOURNAL OF PAIN RESEARCH, 2020, 13 : 605 - 612
  • [22] Efficacy and Safety of Naldemedine for Patients with Cancer with Opioid-Induced Constipation in Clinical Practice: A Real-World Retrospective Study
    Nishiba, Hiromi
    Imai, Hisao
    Fujita, Yukiyoshi
    Hiruta, Eriko
    Masuno, Takashi
    Yamazaki, Shigeki
    Tanaka, Hajime
    Kamiya, Teruhiko
    Ito, Masako
    Takei, Satoshi
    Matsuura, Masato
    Mogi, Junnosuke
    Minato, Koichi
    Obayashi, Kyoko
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)
  • [23] Safety/Efficacy of Prucalopride in Korean Patients with Chronic Constipation: Post-marketing Surveillance
    Yeon, Sang Eun
    Kim, Su Youn
    Chung, Woo Chul
    Jeon, Seong Woo
    Park, Soo Jung
    Choi, Chang Hwan
    Choi, Myung Gyu
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2021, 78 (04): : 219 - 226
  • [24] Safety and effectiveness of rasagiline in patients with Parkinson's disease in Japan: a post-marketing surveillance study
    Hattori, Nobutaka
    Kajita, Mika
    Fujimoto, Shinji
    Izutsu, Miwa
    Fernandez, Jovelle
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (01) : 79 - 88
  • [25] Phase 3 study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation (OIC) in cancer patients.
    Harada, Toshiyuki
    Katakami, Nobuyuki
    Murata, Toru
    Shinozaki, Katsunori
    Tsutsumi, Masakazu
    Yokota, Takaaki
    Arai, Masatsugu
    Suzuki, Yura
    Narabayashi, Masaru
    Boku, Narikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan
    Kawasaki, Akira
    Hatake, Kiyohiko
    Matsumura, Itaru
    Izutsu, Koji
    Hoshino, Tomohiro
    Akamatsu, Ayumi
    Kakuuchi, Akito
    Tobinai, Kensei
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (06) : 667 - 676
  • [27] Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer Reply
    Katakami, Nobuyuki
    Yokota, Takaaki
    Tada, Yukio
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (10) : 1050 - +
  • [28] Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age
    Wild, James
    Webster, Lynn
    Yamada, Tadaaki
    Hale, Martin
    DRUGS & AGING, 2020, 37 (04) : 271 - 279
  • [29] The safety and effectiveness of naldemedine for opioid-induced constipation in patients with advanced cancer in real-world palliative care settings: a multicenter prospective observational study
    Shimizu, Masaki
    Maeda, Isseki
    Kessoku, Takaomi
    Ishiki, Hiroto
    Matsuura, Tetsuya
    Hiratsuka, Yusuke
    Matsuda, Yoshinobu
    Hasegawa, Takaaki
    Imai, Kengo
    Oyamada, Shunsuke
    Satomi, Eriko
    SUPPORTIVE CARE IN CANCER, 2024, 32 (08)
  • [30] Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age
    James Wild
    Lynn Webster
    Tadaaki Yamada
    Martin Hale
    Drugs & Aging, 2020, 37 : 271 - 279
12345